Letrozole (Femara)

Letrozole, sold as Femara, is a pill that lowers the amount of estrogen in your body. It belongs to a class of drugs called aromatase inhibitors (AIs — they block the enzyme that builds estrogen). It is a real, well-studied medicine with strong research behind it, used in cancer care and in fertility treatment. It helps to be clear about what letrozole is and is not: it is not a peptide, not a SERM (a different kind of anti-estrogen drug, like tamoxifen, that blocks estrogen’s signal rather than its production), and not an anabolic steroid. It works by switching off the enzyme that makes estrogen, which lowers estrogen levels throughout the body. In bodybuilding, people use it off-label (for a purpose it was never approved for) to push down the estrogen that builds up when they take certain steroids — a use that has not been approved, has not been studied in that group, is banned in sports, and can cause real harm. This page is here to inform and reduce harm. It gives no doses, cycles, stacks, or post-cycle plans, and no information on where to get the drug.

What it is

Letrozole is a nonsteroidal aromatase inhibitor — a triazole compound (a type of small molecule built around a three-nitrogen ring). It is reversible and competitive, meaning it temporarily occupies the enzyme and lets go again rather than destroying it. The enzyme it targets is aromatase (CYP19A1) — the body’s tool for turning androgens (male-type hormones) into estrogens. It changes testosterone into estradiol and androstenedione into estrone, mostly out in the body’s tissues like fat, muscle, the gonads, and the brain. Letrozole grabs onto the iron core of the aromatase enzyme and shuts down estrogen production.

In postmenopausal women, it cuts circulating estradiol, estrone, and estrone-sulfate (the main forms estrogen travels in) by about 75–95% below where they started, hitting close to its full effect within 2–3 days. At normal treatment doses it does not touch the body’s production of cortisol-type steroids or aldosterone (hormones that handle stress and salt balance). Because it drops estrogen, it also eases the brake that estrogen normally puts on the brain’s hormone control center, so the body releases more FSH and LH (the signals that tell the gonads to work). That one effect explains both its medical use in fertility (more FSH pushes the ovaries to grow follicles) and why men in PED (performance-enhancing drug) circles are drawn to it — it can nudge up a man’s own testosterone and signaling hormones while keeping estrogen in check. One key point: letrozole does not block estrogen receptors. That is what SERMs like tamoxifen do, and they are a separate class of drug.

The claims

Medically, letrozole is used for two main things: (1) HR-positive breast cancer in postmenopausal women — given right after surgery, given as an extended course later on, and used when the cancer has spread; and (2) off-label, to trigger ovulation in women who do not ovulate on their own, including those with PCOS (polycystic ovary syndrome). Other uses being explored — for endometriosis, gynecomastia (breast-tissue growth in men), and certain growth or short-stature situations — are off-label and not as well established.

In the PED context (off-label, illicit, and unapproved), people taking anabolic-androgenic steroids use AIs like letrozole as a “side” drug to hold down the estrogen that forms when their steroids convert into estradiol. The reasons they give are to prevent or treat gynecomastia and estrogen-driven water retention, and to raise their own testosterone and signaling hormones. Letrozole is one of the stronger AIs, which is exactly why “estrogen crashing” — pushing estradiol down too far — is a real problem that users report often. None of these uses come from evidence-based protocols, and no doses, cycles, stacks, or PCT (post-cycle therapy) plans are given here.

What the evidence actually shows

For its approved medical uses, the human research is large and solid.

• Breast cancer — better than tamoxifen (BIG 1-98): This head-to-head trial in postmenopausal women with receptor-positive early breast cancer compared letrozole against tamoxifen after surgery. Letrozole clearly did better at keeping the cancer from coming back (hazard ratio ~0.81–0.82, meaning a lower chance of the disease returning). (Thürlimann et al., NEJM 2005;353:2747-2757; PMID 16382061.)
• Extended treatment (MA.17R): Staying on letrozole for a full 10 years (5 more after an initial 5 years of an AI) further lowered the chance of the cancer returning or appearing in the other breast, and improved 5-year disease-free survival (95% vs 91%) — but it was harder on the bones, with more fractures (14% vs 9%) and more new cases of osteoporosis (11% vs 6%). Living longer overall was not clearly improved (93% vs 94%; HR 0.97, P=0.83). (Goss et al., NEJM 2016;375:209-219; PMID 27264120.)
• Infertility / PCOS (the landmark Legro trial): In a high-quality trial (double-blind RCT, where neither patients nor doctors knew who got which drug) of 750 women with PCOS, letrozole led to more live births over time than clomiphene (27.5% vs 19.1%; rate ratio 1.44) and more ovulation (61.7% vs 48.3%). This is what made it a first-choice drug for triggering ovulation in PCOS. (Legro et al., NEJM 2014;371:119-129; PMID 25006718.)

On PED use specifically: there are no rigorous human trials showing that letrozole is safe or effective for bodybuilding/PED “estrogen management.” Whatever evidence exists there is just anecdotal — and the cancer and fertility studies above do not back up that practice.

Legal and regulatory status

US — prescription (Rx) drug. Letrozole is legal to have and use if you have a valid prescription, and it is not a controlled substance. Selling or handing it out without authorization, or marketing “research chemical” letrozole for people to take, is against the law (it falls into unapproved-drug and misbranding territory). The other anti-estrogens often mentioned alongside it — tamoxifen, anastrozole, exemestane, clomiphene — are also prescription-only and not controlled. Aromatase inhibitors and SERMs are not scheduled (not on the controlled-substance lists).

To keep the legal picture clear, it helps to compare the compounds that tend to come up next to it:

• Mesterolone (Proviron) and fluoxymesterone (Halotestin) are anabolic-androgenic steroids — Schedule III controlled substances in the US under the Anabolic Steroid Control Act (21 CFR 1308.13). Letrozole, SERMs, and AIs are not scheduled.
• DNP (2,4-dinitrophenol) is NOT approved for people to consume in any form. Back in 1938 the FDA declared DNP unfit and unsafe for human use. It has a long, well-documented record of deadly poisonings — it forces the body to release energy as raw heat instead of usable fuel, leading to uncontrolled overheating. It is sold illegally as a “fat-burner,” is not a real medicine, and has no antidote.

Anti-doping (WADA 2026 Prohibited List, in force January 1, 2026). Letrozole is banned at all times — both in and out of competition — under S4, “Hormone and Metabolic Modulators.”

• Aromatase inhibitors — the S4 list names letrozole, anastrozole, exemestane, formestane, and testolactone, among others.
• Anti-estrogenic substances and SERMs — S4 names clomifene, tamoxifen, toremifene, raloxifene, and fulvestrant, among others.
• 2026 additions to S4 worth noting here: α-naphthoflavone (7,8-benzoflavone) is now listed as an example of an aromatase inhibitor, and BAM15 is listed as an example of an AMP-activated protein kinase (AMPK) activator — it is a mitochondrial uncoupler (a substance that makes cells burn energy as heat). Both were flagged for showing up in supplements and “research chemicals.” (Verified via the USADA 2026 advisory.)
• Insulin is banned under S4 (insulins and insulin-mimetics).

For context: anabolic agents (steroids such as mesterolone and fluoxymesterone) fall under S1. T3 / thyroid hormone is not currently on the WADA Prohibited List.

Safety

Most of the trouble with letrozole and other AIs comes from the same thing: cutting estrogen too low.

• Bone: bone thinning, osteopenia/osteoporosis (weakened bone), and a higher chance of fractures — clearly seen in MA.17R (14% vs 9% fractures; 11% vs 6% new osteoporosis), because estrogen helps protect bone.
• Joints and muscle: joint aches (arthralgia), stiffness, and muscle aches (myalgia).
• Cholesterol / heart: unfavorable changes in blood fats (lipids) and some heart-related warning signs.
• Other: hot flashes, tiredness, and mood changes. In men using it off-label, crashing estradiol can bring on joint pain, low sex drive, erectile dysfunction, sluggishness, and bone loss — estradiol matters for a man’s bones, libido, and cholesterol, so driving it down with an AI is genuinely harmful, not harmless.
• Pregnancy: letrozole can harm a developing baby (it is a teratogen) and must not be used during pregnancy. When it is used to trigger ovulation, the timing is set on purpose before conception so the baby is never exposed.

Why PED self-experimentation around letrozole is dangerous comes down in large part to the other compounds people combine with it:

• DNP (2,4-dinitrophenol) — the deadliest item in this space. DNP kills people. It makes the body release its energy as heat instead of storing it, so the temperature climbs out of control and can be fatal (body temperatures reported as high as ~44 °C / 111 °F), along with a racing heart, heavy sweating, agitation, and failure of multiple organs. There is no antidote and no known safe dose — deaths happen even at “recommended” amounts, sometimes hours after the last dose. All doctors can do is cool the body and provide supportive care, and deaths are on record, including in recent decades.
• Insulin (used by non-diabetics for a muscle-building or nutrient-shuttling effect): can cause severe, life-threatening low blood sugar, seizures, permanent brain damage, and death — especially without careful carbohydrate monitoring. It is a known cause of bodybuilder deaths.
• SERMs (tamoxifen, clomiphene, raloxifene): can raise the risk of dangerous blood clots (deep vein thrombosis, pulmonary embolism, stroke), cause vision changes (with clomiphene), hot flashes, and mood changes; tamoxifen also carries a risk of uterine (endometrial) cancer with long-term cancer use.
• T3 / liothyronine (a thyroid hormone used for fat loss): can strain the heart (irregular or rapid heartbeats, atrial fibrillation, palpitations, extra workload on the heart), shut down the body’s own thyroid signaling so the thyroid lags when the drug stops, cause bone loss with long-term overuse, and break down muscle.

Bottom line

Letrozole is a real, FDA-approved drug with strong research behind it in cancer and fertility care — a nonsteroidal, reversible aromatase inhibitor, not a peptide and not a SERM. But it is powerful at lowering estrogen and brings real costs to the bones, blood fats, and joints. Its bodybuilding/PED use to control estrogen is off-label, unapproved, untested in that group, banned in sport (WADA S4), and capable of real harm — especially the sexual, mood, and bone problems that come from crashing estrogen in men. The wider “PED-support” group it gets lumped in with — DNP, insulin, T3 — includes some of the most immediately deadly substances out there, DNP most of all, which kills through unstoppable overheating and has no antidote. Any use should be supervised by a doctor.

Evidence grade: 10/10 · Established.

Sources

• Legro RS et al., 2014 — Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome, N Engl J Med 371:119-129 (PMID 25006718)
• Goss PE et al., 2016 — Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years (MA.17R), N Engl J Med 375:209-219 (PMID 27264120)
• Thürlimann B et al. (BIG 1-98), 2005 — A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer, N Engl J Med 353:2747-2757 (PMID 16382061)
• Cohen MH et al., 2002 — Approval Summary: Letrozole in the Treatment of Postmenopausal Women with Advanced Breast Cancer, Clin Cancer Res 8(3):665-669
• Cohen MH et al., 2011 — Approval Summary: Letrozole (Femara) for Adjuvant and Extended Adjuvant Postmenopausal Breast Cancer Treatment, The Oncologist (PMC3248775)
• FDA — FEMARA (letrozole) tablets, prescribing information (2024 label)
• WADA — The Prohibited List (S4 Hormone and Metabolic Modulators)
• USADA — Athlete Advisory: What’s New on the 2026 WADA Prohibited List? (α-naphthoflavone and BAM15 added to S4)
• Letrozole — mechanism and approval overview (Wikipedia)
• 2,4-Dinitrophenol — 1938 FDA action, uncoupling mechanism, fatal hyperthermia, no antidote (Wikipedia)